Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.

Creary SE, Gladwin MT, Byrne M, Hildesheim M, Krishnamurti L.

Pediatr Blood Cancer. 2014 Jun;61(6):1068-73. doi: 10.1002/pbc.24931. Epub 2014 Jan 16.

PMID:
24436121
[PubMed - indexed for MEDLINE]
2.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

PMID:
8982148
[PubMed - indexed for MEDLINE]
3.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
[PubMed - indexed for MEDLINE]
4.

Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.

Borba R, Lima CS, Grotto HZ.

J Clin Lab Anal. 2003;17(2):66-72.

PMID:
12640630
[PubMed - indexed for MEDLINE]
5.

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Acta Haematol. 1995;94(3):128-34.

PMID:
7502628
[PubMed - indexed for MEDLINE]
6.

[Sickle cell anemia in children: value of hydroxyurea in severe forms].

Oury AP, Hoyoux C, Dresse MF, Chantraine JM.

Arch Pediatr. 1997 Sep;4(9):839-44. French.

PMID:
9345564
[PubMed - indexed for MEDLINE]
7.

Adherence to hydroxyurea therapy in children with sickle cell anemia.

Thornburg CD, Calatroni A, Telen M, Kemper AR.

J Pediatr. 2010 Mar;156(3):415-9. doi: 10.1016/j.jpeds.2009.09.044. Epub 2009 Nov 1.

PMID:
19880135
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Hydroxyurea for the treatment of sickle cell disease.

Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S.

Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Review.

PMID:
18457478
[PubMed - indexed for MEDLINE]
Free Article
9.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
[PubMed - indexed for MEDLINE]
10.

Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.

Tavakkoli F, Nahavandi M, Wyche MQ, Castro O.

Clin Ther. 2005 Jul;27(7):1083-8.

PMID:
16154487
[PubMed - indexed for MEDLINE]
11.

Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.

Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FI, Bassi SC, Santis GC, Covas DT.

Sao Paulo Med J. 2013;131(4):238-43. doi: 10.1590/1516-3180.2013.1314467.

PMID:
24141294
[PubMed - indexed for MEDLINE]
Free Article
12.

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.

Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galactéros F, Girard P, Hulin A, Tod M.

Orphanet J Rare Dis. 2011 May 28;6:30. doi: 10.1186/1750-1172-6-30.

PMID:
21619673
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Hydroxyurea in children: present and future.

Vichinsky EP.

Semin Hematol. 1997 Jul;34(3 Suppl 3):22-9. Review.

PMID:
9317198
[PubMed - indexed for MEDLINE]
14.

Use of hydroxyurea in children with sickle cell disease: what comes next?

Ohene-Frempong K, Smith-Whitley K.

Semin Hematol. 1997 Jul;34(3 Suppl 3):30-41. Review.

PMID:
9317199
[PubMed - indexed for MEDLINE]
15.

Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy.

Saleh AW, Hillen HF, Duits AJ.

Acta Haematol. 1999;102(1):31-7.

PMID:
10473885
[PubMed - indexed for MEDLINE]
16.

Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.

Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K, Asakura T.

Br J Haematol. 2005 Nov;131(3):389-94.

PMID:
16225659
[PubMed - indexed for MEDLINE]
17.

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

Charache S.

Semin Hematol. 1997 Jul;34(3 Suppl 3):15-21. Review.

PMID:
9317197
[PubMed - indexed for MEDLINE]
18.

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.

Blood. 1999 Sep 1;94(5):1550-4.

PMID:
10477679
[PubMed - indexed for MEDLINE]
Free Article
19.

Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.

Salvia AC, Figueiredo MS, Braga JA, Pereira DF, Brighenti FL, Koga-Ito CY.

J Oral Pathol Med. 2013 Aug;42(7):570-5. doi: 10.1111/jop.12029. Epub 2012 Dec 26.

PMID:
23278631
[PubMed - indexed for MEDLINE]
20.

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.

Blood. 1997 Apr 1;89(7):2554-9.

PMID:
9116302
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk